Hormonal
Early Time-Restricted Eating (eTRE) with an 8-hour window starting before noon significantly reduces body weight and fat mass while improving glycemic markers (fasting glucose, insulin, HOMA-IR) and triglycerides in young adults with delayed sleep-wake cycles, whereas late TRE (starting after noon) fails to produce these metabolic benefits.
If you are a young adult with a late sleep schedule, try shifting your eating window to start before noon (e.g., 8am-4pm or 9am-5pm) for 4 weeks. Ensure you get about 20g of extra protein daily (via snacks or shakes) to protect muscle. This specific timing appears necessary to reduce fat and improve blood sugar control; starting your window after noon may not yield these metabolic benefits.
Body weight and fat mass, excluding muscle mass, were significantly reduced over 4 weeks compared to baseline only in the early TRE group starting before noon. The early TRE group also showed significantly reduced fasting glucose, fasting insulin, and serum triglyceride (TG) levels after 4 weeks. However, the late TRE group starting after noon showed no significant changes except a reduced TG level.
Why this rating
Single-arm, pre-post intervention study with a small sample size (n=34) and short duration (4 weeks); lacks a control group and long-term follow-up.
Source
Early Time-Restricted Eating Reduces Weight and Improves Glycemic Response in Young Adults: A Pre-Post Single-Arm Intervention Study
Jina Kim et al. · Obesity Facts · 2022
DOI 10.1159/000527838
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →